OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $61.17 +1.55 (+2.60%) As of 10/23/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartInsider TradesNews and TrendsOwnershipShort Interest About Roche Stock (OTCMKTS:RHHBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roche alerts:Sign Up Key Stats Today's Range$59.00▼$61.4950-Day Range$51.88▼$61.1752-Week Range$40.07▼$61.49Volume2.61 million shsAverage Volume1.39 million shsMarket Capitalization$389.69 billionP/E RatioN/ADividend Yield1.59%Price Target$60.00Consensus RatingModerate Buy Company Overview Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases. The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions. Roche also operates a diagnostics business that provides in-vitro diagnostic systems, laboratory tests, tissue-based diagnostics and digital health solutions for hospitals, laboratories, physicians and patients. Roche serves healthcare providers and patients worldwide through operations and commercial activities across numerous geographic markets. Its global business includes Genentech in the United States, which operates as a member of the Roche Group and supports the company’s pharmaceutical research and development activities. Thomas Schinecker has served as Roche’s chief executive officer since 2023, while Severin Schwan is chairman of the company’s board of directors. Roche’s shares trade in Switzerland, and its American depositary receipts trade on the over-the-counter market under the symbol RHHBY.AI Generated. May Contain Errors. Read More Roche Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreRHHBY MarketRank™: 2.70757880617 of 5 starsRoche scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingRoche has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 8 buy ratings, 5 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Roche is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageRoche has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roche's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.28% Earnings GrowthEarnings for Roche are expected to grow by 7.28% in the coming year, from $3.02 to $3.24 per share.Price to Earnings Growth RatioRoche has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoche has a P/B Ratio of 8.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Roche has been sold short.Short Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 1.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roche has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRoche pays a meaningful dividend of 1.59%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoche does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Roche will have a dividend payout ratio of 29.94% next year. This indicates that Roche will be able to sustain or increase its dividend.Read more about Roche's dividend. News and Social Media2.6 / 5News Sentiment0.09 News SentimentRoche has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Roche this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for RHHBY on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows5 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roche insiders have not sold or bought any company stock.Percentage Held by InstitutionsRoche has minimal institutional ownership at this time.Read more about Roche's insider trading history. Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RHHBY Stock News HeadlinesRoche says divarasib cut risk of death 44% in lung cancer trial42 minutes ago | reuters.comRoche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer2 hours ago | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 25 at 1:00 AM | Porter & Company (Ad)Roche (OTCMKTS:RHHBY) Sets New 12-Month High - Here's WhyOctober 25 at 4:21 AM | americanbankingnews.comRoche Reports Positive Phase III Data For Investigational IgAN Therapy SefaxersenOctober 24 at 9:29 AM | rttnews.comGenentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)October 23 at 1:30 PM | businesswire.comRoche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)October 23 at 1:30 PM | globenewswire.comThere's a New Q in Town: Invesco's ETF Targets International Innovators (RHHBY)Invesco recently launched QQI, an ETF tracking the Nasdaq International Innovators 100 Index, offering tech- and healthcare-heavy exposure to non-U.S. growth companies with higher costs and lower liquidity than QQQ.October 22 at 9:15 AM | marketbeat.comSee More Headlines RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $51.57 at the beginning of the year. Since then, RHHBY stock has increased by 18.6% and is now trading at $61.17. Does Roche have any subsidiaries? Roche subsidiaries include these companies: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and more. Who are Roche's major shareholders? Top institutional investors of Roche include GAMMA Investing LLC and Woodstock Corp. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roche own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roche investors own include Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Bristol Myers Squibb (BMY), Intel (INTC) and Walt Disney (DIS). Company Calendar Today10/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RHHBY CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,249Year Founded1896Price Target and Rating Average Price Target for Roche$60.00 High Price Target$63.00 Low Price Target$57.00 Potential Upside/Downside-1.9%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio20.25 P/E Growth3.87Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.69 Current Ratio1.23 Quick Ratio0.95 Sales & Book Value Annual Sales$76.45 billion Price / Sales5.10 Cash Flow$3.60 per share Price / Cash Flow16.99 Book Value$7.18 per share Price / Book8.52Miscellaneous Outstanding Shares6,370,540,000Free FloatN/AMarket Cap$389.69 billion OptionableNot Optionable Beta0.45 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:RHHBY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.